RGD-DA6

RGD-DA6 is an αvβ3-targeted ligand. RGD-DA6 consists of RGDfK (an integrin αvβ3-targeted RGD peptide), DOTADG, d-Glu, Lys, AMBA, and IPBA. RGD-DA6 can be radiolabeled as an αvβ3-targeted radioligand and used for high-contrast tumor imaging and enhanced anticancer efficacy[1].

Product Specifications

UNSPSC

12352005

Target

Integrin

Related Pathways

Cytoskeleton

Field of Research

Cancer

Smiles

O=C(NCCCC[C@@H]1NC([C@H](NC([C@@H](NC(CNC([C@@H](NC1=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CC2=CC=CC=C2)=O)CCC(N(CCN(CC3)CC(O)=O)CCN(CC(O)=O)CCN3C(CCC(N[C@@H](C(N[C@@H](CCCCNC(C4=CC=C(C=C4)CNC(CCCC5=CC=C(C=C5)I)=O)=O)C(O)=O)=O)CCC(O)=O)=O)C(O)=O)C(O)=O

Molecular Formula

C78H110IN17O24

Molecular Weight

1796.71

References & Citations

[1]Kazuta N, et al. Development of Novel Integrin αvβ3‑Targeted Radioligand for Enhanced Tumor Accumulation. ACS Med Chem Lett. 2025 Jun 30;16 (7) :1346-1353.